SAB Biotherapeutics, Inc.
SABS
$1.79
$0.03992.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -11.39M | -10.35M | -7.34M | -5.03M | -22.86M |
| Total Depreciation and Amortization | 785.70K | 966.90K | 1.06M | 1.98M | 944.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.96M | 994.30K | -1.70M | -4.93M | 8.89M |
| Change in Net Operating Assets | -1.88M | 2.10M | 263.30K | -2.77M | -427.40K |
| Cash from Operations | -9.53M | -6.29M | -7.72M | -10.75M | -13.45M |
| Capital Expenditure | -55.40K | -100.30K | -52.50K | -129.10K | -67.90K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 9.39M | -1.05M | 11.27M | -31.23M | -- |
| Cash from Investing | 9.33M | -1.15M | 11.22M | -31.36M | -67.90K |
| Total Debt Issued | 516.00K | -- | -- | -- | 765.20K |
| Total Debt Repaid | -274.10K | -649.10K | -252.30K | -247.40K | -287.40K |
| Issuance of Common Stock | -- | 0.00 | 0.00 | 20.40K | 59.66M |
| Repurchase of Common Stock | -24.90K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 7.50M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -25.00K | -68.70K | -167.40K | -- |
| Cash from Financing | 217.00K | -674.10K | -321.00K | -394.40K | 67.64M |
| Foreign Exchange rate Adjustments | -288.70K | 47.50K | 28.30K | -28.30K | 18.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -273.20K | -8.07M | 3.21M | -42.53M | 54.14M |